Perspective · 19 Mar 2025
CommentaryPublished 2016
The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The discovery that immunotherapy is a clinically-relevant approach for the treatment of malignant tumors is revolutionizing patient care. In adults diagnosed with glioblastoma (GBM), an aggressive and incurable primary brain tumor, autologous HSPPC-96 vaccination provides a significant increase in overall survival. However, all GBM patients eventually succumb to their disease, providing rationale for discovering new methods that proactively identify individuals that will respond, optimally. Of the immunosuppressive mediators that contribute to the inhibition of productive tumor immunity, indoleamine 2,3 dioxygenase 1 (IDO1), a rate-limiting enzyme that catabolizes tryptophan (Trp) into kynurenine (Kyn), has been demonstrated to be expressed at elevated levels in patients with malignant glioma. Recently, our group determined that a correlation exists between peripheral blood Trp and Kyn levels in GBM patients and the association with overall survival after HSPPC-96 treatment. Our findings indicate that the Kyn/Trp ratio may be a useful benchmark for identifying GBM patients with a higher likelihood to survive longer after vaccination. The relevance to future clinical trials, the limitations of brain tumor models to address these findings and the role of IDO1 versus tryptophan dioxygenase (TDO) in the maintenance of peripheral Trp and Kyn levels, is discussed.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunotherapy: Open Access.
Perspective · 19 Mar 2025
Advancing Immunotherapy: Future Directions in the Fight against Renal Cell Carcinoma
Short communication · 19 Mar 2025
Emerging Therapies: The Latest Developments in Autoimmune Disease Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunotherapy: Open Access
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Alicia Lenzen”
- BylineArticles whose byline prints “Lijie Zhai”
- BylineArticles whose byline prints “Kristen L Lauing”
- BylineArticles whose byline prints “Galina Gritsina”
- BylineArticles whose byline prints “Erik Ladomersky”
- BylineArticles whose byline prints “Matthew Genet”
- BylineArticles whose byline prints “C David James”
- BylineArticles whose byline prints “Orin Bloch”
